Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation

Aine McKillop, Nicola Duffy, John Lindsay, Brian Green, Steven Patterson, Finbarr O'Harte, Patrick Bell, Peter Flatt

Research output: Contribution to journalArticle

Abstract

Nateglinide restores early-phase insulin secretion to feeding and reduces postprandial hyperglycaemia in type 2 diabetes. This study evaluated the effects of nateglinide on dipeptidyl peptidase-IV (DPP-IV) activity and glucose-dependent insulinotropic polypeptide (GIP) degradation. Research design and methods Blood samples were collected from type 2 diabetic subjects (n=10, fasting glucose 9.36+/-1.2 mmol/l) following administration of oral nateglinide (120 mg) 10 min prior to a 75 g oral glucose load in a randomised crossover design.
Original languageEnglish
Pages (from-to)877-885
Number of pages9
JournalEuropean Journal of Endocrinology
Volume161
Issue number6
DOIs
Publication statusPublished - Dec 2009

Keywords

  • diabetes
  • insulin secretion
  • nateglinide
  • postprandial hyperglycaemia

Fingerprint Dive into the research topics of 'Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation'. Together they form a unique fingerprint.

  • Cite this